<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33583245</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1473-2300</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>49</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of international medical research</Title>
          <ISOAbbreviation>J Int Med Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acute-onset paraneoplastic cerebellar degeneration secondary to neuroendocrine carcinoma with atypical prognosis: a case report.</ArticleTitle>
        <Pagination>
          <StartPage>300060521992231</StartPage>
          <MedlinePgn>300060521992231</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">0300060521992231</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/0300060521992231</ELocationID>
        <Abstract>
          <AbstractText>Paraneoplastic cerebellar degeneration (PCD) is a neurological syndrome that is likely caused by tumor-induced autoimmunity against the cerebellum. Neuroendocrine carcinoma (NEC) is a type of neoplasm with high-grade malignant histology and biological behavior. The prognosis for both PCD and NEC is typically poor. We report a case of PCD secondary to metastatic NEC in the lymph nodes, with an unknown primary origin. The case presented acute cerebellar manifestations with typical neuroimaging findings, but with atypical prognosis after lymph node dissection. Neurological symptoms can provide clues to potential tumors, and early antitumor treatment may have contributed to the positive prognosis of PCD secondary to NEC in the present case.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Kunyu</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Miao</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ning</LastName>
            <ForeName>Haoyong</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nuclear Medicine, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bian</LastName>
            <ForeName>Yang</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-4002-5646</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Qingqing</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Chenjing</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Xiaokun</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0001-6931-1219</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Int Med Res</MedlineTA>
        <NlmUniqueID>0346411</NlmUniqueID>
        <ISSNLinking>0300-0605</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018278" MajorTopicYN="Y">Carcinoma, Neuroendocrine</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002531" MajorTopicYN="N">Cerebellum</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020362" MajorTopicYN="Y">Paraneoplastic Cerebellar Degeneration</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Paraneoplastic neurological syndromes</Keyword>
        <Keyword MajorTopicYN="N">acute cerebellar manifestation</Keyword>
        <Keyword MajorTopicYN="N">metastasis</Keyword>
        <Keyword MajorTopicYN="N">neuroendocrine carcinoma</Keyword>
        <Keyword MajorTopicYN="N">paraneoplastic cerebellar degeneration</Keyword>
        <Keyword MajorTopicYN="N">tumor</Keyword>
      </KeywordList>
      <CoiStatement><b>Declaration of conflicting interest:</b> The authors declare that there is no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>15</Day>
          <Hour>5</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33583245</ArticleId>
        <ArticleId IdType="pmc">PMC7890730</ArticleId>
        <ArticleId IdType="doi">10.1177/0300060521992231</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Leypoldt F, Wandinger KP.
Paraneoplastic neurological syndromes.
Clin Exp Immunol
2014; 
175: 336–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3927895</ArticleId>
            <ArticleId IdType="pubmed">23937626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giometto B, Grisold W, Vitaliani R, et al.
Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers.
Arch Neurol
2010; 
67: 330–335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20212230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig A, Gigli GL, Segatti S, et al.
Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol
2020; 
267: 26–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31552550</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rindi G, Klimstra DS, Abedi-Ardekani B, et al.
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.
Mod Pathol
2018; 
31: 1770–1786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6265262</ArticleId>
            <ArticleId IdType="pubmed">30140036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zandee WT, Van Der Zwan JM, De Herder WW, et al.
Importance of complete pathology reporting for neuroendocrine carcinoma: WHO guidelines are a good start but not enough.
Neuroendocrinology
2020; 
110: 994–1000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31995804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rojas I, Graus F, Keime-Guibert F, et al.
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.
Neurology
2000; 
55: 713–715.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10980743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkatraman A, Opal P.
Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review.
Ann Clin Transl Neurol
2016; 
3: 655–663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4999597</ArticleId>
            <ArticleId IdType="pubmed">27606347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shams'ili S, Grefkens J, De Leeuw B, et al.
Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.
Brain
2003; 
126: 1409–1418.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12764061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Key RG, Root JC.
Anti-Yo mediated paraneoplastic cerebellar degeneration in the context of breast cancer: a case report and literature review.
Psychooncology
2013; 
22: 2152–2155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23585287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig A, Bernardini A, Gigli GL, et al.
Stroke-like presentation of paraneoplastic cerebellar degeneration: a single-center experience and review of the literature.
Cerebellum
2019; 
18: 976–982.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31463826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graus F, Delattre JY, Antoine JC, et al.
Recommended diagnostic criteria for paraneoplastic neurological syndromes.
J Neurol Neurosurg Psychiatry
2004; 
75: 1135–1140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1739186</ArticleId>
            <ArticleId IdType="pubmed">15258215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walter T, Tougeron D, Baudin E, et al.
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Eur J Cancer
2017; 
79: 158–165.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28501762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenlee JE.
Treatment of paraneoplastic cerebellar degeneration.
Curr Treat Options Neurol
2013; 
15: 185–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7102346</ArticleId>
            <ArticleId IdType="pubmed">23315179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mirallas O, Rezqallah Arón MA, Saoudi Gonzalez N, et al.
Paraneoplastic cerebellar degeneration diagnosed by anti-Yo determination in a young woman with early breast cancer. BMJ Case Rep
2020; 
13: e233863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7449566</ArticleId>
            <ArticleId IdType="pubmed">32843422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin AN, Dillon PM, Jones DE, et al.
Anti-Yo mediated paraneoplastic cerebellar degeneration associated with pseudobulbar affect in a patient with breast cancer.
Case Rep Oncol Med
2017; 
2017: 8120689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5362719</ArticleId>
            <ArticleId IdType="pubmed">28377827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Candler PM, Hart PE, Barnett M, et al.
A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry
2004; 
75: 1411–1415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1738729</ArticleId>
            <ArticleId IdType="pubmed">15377687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simard C, Vogrig A, Joubert B, et al.
Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm
2020; 
7: e699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7136048</ArticleId>
            <ArticleId IdType="pubmed">32170042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogrig A, Pauletto G, Belgrado E, et al.
Effect of thymectomy on refractory autoimmune status epilepticus.
J Neuroimmunol
2018; 
317: 90–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29336839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumari VA, Gupta P, Srivastava MV, et al.
Paraneoplastic cerebellar degeneration as the first evidence of malignancy: a case report.
J Obstet Gynaecol Res
2014; 
40: 1463–1465.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24689522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takasugi J, Shimamura M, Koda T, et al.
Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with neuroendocrine carcinoma of the oropharynx.
Intern Med
2018; 
57: 587–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5849558</ArticleId>
            <ArticleId IdType="pubmed">29093415</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorbye H, Welin S, Langer SW, et al.
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol
2013; 
24: 152–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22967994</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
